A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients

Diabetes

Volumn 48, Issue 12, 1999, Pages 2414-2421

  Yu, Joseph G ^a   Kruszynska, Yolanta T ^a   Mulford, Mim I ^a   Olefsky, Jerrold M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; TROGLITAZONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0033507350     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.12.2414     Document Type: Article

References (55)

1. Kruszynska YT, Olefsky JM: Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus. J Invest Med 44:413-428, 1996
2. Ohkuho Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus a randomized prospective 6-year study. Diabetes Res Clin Prac 28:103-117, 1995
3. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
4. Yki-Jarvinen H: Glucose toxicity. Endocrine Rev 13:415-431, 1992
5. Leahy JL, Bonner-Weir S, Weir GC: β-Cell dysfunction induced by chronic hyperglycemia. Diabetes Care 15:442-455, 1992
6. UKPDS Group: U.K. Prospective Diabetes Study 17: a nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124:136-145, 1996
7. Nabarro JD: Oral hypoglycaemic agents: the first thirty years. J R Coll Physicians Lond 26:50-55, 1992
8. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS: Intensive conventional insulin therapy for type 2 diabetes. Diabetes Care 16:21-31, 1993
9. UKPDS Group: United Kingdom Prospective Diabetes Study 24: a 6 year, randomized controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Int Med 128:165-175, 1998
10. Pyorala K, Laakso M, Uusitupa M: Diabetes and arteriosclerosis: an epidemiologic view. Diabetes Metab Rev 3:463-524, 1987
11. Despres J-P, Lamarche B, Mauriege P, Cantin B, Degenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996
12. Golay A, Guillet-Dauphine N, Fendel A, Juge C, Assal JP: The insulin-sparing effect of metformin in insulin-treated diabetic patients. Diabetes Metab Rev 11:S63-S67, 1995
13. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, D'Onofrio F: Metformin for obese, insulin-treated diabetic patients: improvement in glycemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 44:107-112, 1993
14. Slama G: The insulin sparing effect of metformin in insulin-treated diabetic patients. Diabet Metab 17:241-243, 1991
15. Schwartz S, Raskin P, Fonseca V, Graveline JF: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 338:861-866, 1998
16. Henry RR: Thiazolidinediones. Endocrinol Metab Clin N Am 26:553-573, 1997
17. DeFronzo RA, Barzilai N, Simonson DC: Mechanism of metformin action in obese and lean non-insulin dependent diabetic subjects. J Clin Endocrinol Metab 73:1294-1301, 1991
18. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872, 1998
19. Jackson RA, Hawa MI, Jaspan JB, Sim BM, DiSilvio L, Featherbe D, Kurtz AB: Mechanism of metformin action in non-insulin dependent diabetes. Diabetes 36:632-640, 1987
20. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich J: Metabolic effects of metformin in non-insulin dependent diabetes mellitus. N Engl J Med 333:550-554, 1995
21. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, Ventura MM, Santeusanio F, Brunetti P, Bolli GB: Acute anti-hyperglycemic mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 43:920-928, 1994
22. Prigeon RL, Kahn SE, Porte D Jr: Effect of troglitazone on β cell function, insulin sensitivity and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 83:819-823, 1998
23. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
24. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
25. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double blind, placebo-controlled trial. Ann Int Med 128:176-185, 1998
26. Reaven GM: Effect of metformin on various aspects of glucose, insulin and lipid metabolism in patients with non-insulin-dependent diabetes mellitus with varying degrees of hyperglycemia. Diabetes Metab Rev 11:S97-S108, 1995
27. Hother-Nielsen O, Schmitz O, Andersen PH, Beck-Nielsen H, Pedersen O: Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol 120:257-265, 1989
28. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222-234, 1985
29. Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, Reaven GM: Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 33:634-642, 1984
30. Yki-Jarvinen H, Nikkila E, Eero H, Taskinen MR: Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type II diabetic patients with secondary drug failure. Am J Med 84:185-192, 1988
31. Kosaka K, Kuzuya T, Akanuma Y, Hagura R: Increase in the insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 18:23-28, 1980
32. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
33. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 37:E214-E223, 1979
34. Finegood DT, Bergman RN, Vranic V: Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps: comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 36:914-924, 1987
35. Wolfe RR: Tracers in Metabolic Research: Radioisotope/Mass Spectrometry Methods. New York, Alan R. Liss, 1984, p. 81-101
36. Steele R: Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82:420-430, 1959
37. Desbuquois B, Aurbach GD: Use of polyethylene glycol to separate free and antibody bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 33:732-738, 1971
38. Faber OK, Binder C, Markussen J, Heding LG, Naithani VK, Kazuga H, Blix P, Horwitz DL, Rubenstein AH: Characterization of seven C-peptide antisera. Diabetes 27 (Suppl. 1):170-177, 1978
39. Kruszynska YT, Mulford MI, Baloga J, Yu JG, Olefsky JM: Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetes 47:1107-1113, 1998
40. Wu MS, Johnston P, Sheu WHH, Hollenbeck CB, Jeng CY, Goldfine ID, Chen YDI, Reaven GM: Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 13:1-8, 1990
41. Bak JF, Schmitz O, Sorensen NS, Pedersen O: Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients. Diabetes 38:1343-1350, 1989
42. Henry RR, Wallace P, Olefsky JM: The effects of weight loss on the mechanisms of hyperglycemia in obese noninsulin-dependent diabetes mellitus. Diabetes 35:990-998, 1986
43. Ferrannini E, Groop LC: Hepatic glucose production in insulin-resistant states. Diabetes Metab Rev 5:711-725, 1989
44. Wollen N, Bailey CJ: Inhibition of hepatic gluconeogenesis by metformin: synergism with insulin. Biochem Pharmacol 37:4353-4358, 1988
45. Radziuk J, Zhang Z, Wiernsperger N, Pye S: Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes 46:1406-1413, 1997
46. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky JM: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
47. Rebrin K, Steil GM, Mittelman S, Bergman RN: Causal linkage between insulin regulation of lipolysis and liver glucose output. J Clin Invest 98:741-749, 1996
48. Kruszynska YT, Mulford MI, Yu JG, Armstrong DA, Olefsky JM: Effects of non-esterified fatty acids on glucose metabolism after glucose ingestion. Diabetes 46:1586-1593, 1997
49. Sindelar DK, Chu CA, Rohlie M, Neal DW, Swift LL, Cherrington AD: The role of fatty acids in mediating the effects of peripheral insulin on hepatic glucose production in the conscious dog. Diabetes 46:187-196, 1997
50. Taskinen MJ, Kuusi T, Helve E, Nikkila EA, Yki-Jarvinen H: Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 8:168-177, 1988
51. Gregorio F, Filipponi P, Ambrosi F, Cristallini S, Marchetti P, Calafiore R, Navalesi R, Brunetti P: Metformin potentiates β-cell response to high glucose: an in vitro study on isolated perfused pancreas from normal rats. Diabet Metab 15:111-117, 1989
52. Marchetti P, Scharp DW, Giannarelli R, Benzi L, Cecchetti P, Ciccarone AM, Lacy PE, Navalesi R: Metformin potentiates glucose-stimulated insulin secretion. Diabetes Care 19:781-782, 1996
53. Shimbukuro M, Zhou YT, Lee Y, Unger RH: Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 273: 3547-3550, 1998
54. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS: Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100:530-537, 1997
55. Garber AJ, Duncan TC, Goodman AM, Mills DJ, Rohlf JL: Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 102:491-497, 1997